Skip to main content

Kintara Therapeutics, Inc. (KTRA)

NASDAQ: KTRA · Delayed Price · USD
1.29
-0.01 (-0.77%)
After-hours:Sep 20, 2021 7:19 PM EDT
1.30
-0.10 (-7.14%)
At close: Sep 20, 4:00 PM
Market Cap45.67M
Revenue (ttm)n/a
Net Income (ttm)-38.59M
Shares Out29.27M
EPS (ttm)-1.87
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume510,297
Open1.37
Previous Close1.40
Day's Range1.27 - 1.39
52-Week Range1.18 - 3.35
Beta1.54
Analystsn/a
Price Target5.81 (+346.9%)
Est. Earnings Daten/a

About KTRA

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic b...

IndustryBiotechnology
Founded2009
CEOSaiid Zarrabian
Employees4
Stock ExchangeNASDAQ
Ticker SymbolKTRA
Full Company Profile

Financial Performance

Financial Statements

News

Kintara Therapeutics Provides Positive Site Activation Update on GCAR Phase 2/3 Clinical Trial for Glioblastoma

SAN DIEGO, Aug. 17, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapie...

1 month ago - PRNewsWire

Kintara Therapeutics to Present at the Investor Summit Virtual Conference on August 17, 2021

SAN DIEGO, Aug. 12, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA), a biopharmaceutical company developing novel cancer therapies for patients who are failing or are resistant to current...

1 month ago - PRNewsWire

Kintara Therapeutics to Present at the BTIG Virtual Biotechnology Conference on August 9, 2021

SAN DIEGO, Aug. 4, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA), a biopharmaceutical company developing novel cancer therapies for patients who are failing or are resistant to current ...

1 month ago - PRNewsWire

Kintara Therapeutics Shows Encouraging Safety, Efficacy Data From Brain Cancer Study With VAL-083

Kintara Therapeutics Inc (NASDAQ: KTRA) has announced topline data from Phase 2 study of its lead compound VAL-083, conducted at the MD Anderson Cancer Center. The Phase 2 trial is a two-arm, biomarker-...

2 months ago - Benzinga

Kintara Reports Topline Results From Phase 2 Clinical Trial of VAL-083 for Recurrent GBM

SAN DIEGO, July 1, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company developing novel cancer therapies for patients who are failing...

2 months ago - PRNewsWire

7 Stocks to Buy Under $5 for Big Gains

If you really want to take a walk on the wild side, there are several stocks to buy under $5. But be prepared for unpredictability.

2 months ago - InvestorPlace

Kintara Therapeutics set to join the Russell Microcap Index

Kintara Therapeutics Inc (NASDAQ:KTRA) (OTCMKTS:DMPWW) (FRA:3DM), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, has announced its addition to the Russell Mi...

3 months ago - Proactive Investors

Kintara Therapeutics Set to Join Russell Microcap® Index

SAN DIEGO, June 7, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies...

3 months ago - PRNewsWire

Dow pulls to above the flatline after morning struggles as traders digest jobs data

12:30pm: Nasdaq finds little upward momentum The Dow clawed its way out of an early deficit to 15 points higher at midday at 34,615. The Nasdaq was down 117 points, 0.9%, at 13,641, and the S&P 500 shed...

Other symbols:CLSK
3 months ago - Proactive Investors

Kintara Therapeutics enrolls last patient in Phase 2 VAL-083 trial for glioblastoma multiforme

Kintara Therapeutics Inc (NASDAQ:KTRA) (FRA:3DM) announced it has enrolled the final patient in the adjuvant arm of its ongoing Phase 2 clinical study of VAL-083 as a treatment for glioblastoma multifor...

3 months ago - Proactive Investors

Kintara Therapeutics Enrolls Final Patient in Phase 2 Clinical Trial of VAL-083 for Adjuvant Treatment of Brain Tumors

SAN DIEGO, June 3, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies...

3 months ago - PRNewsWire

Kintara Therapeutics to Present at the LD Micro Virtual Invitational Conference on June 9, 2021

SAN DIEGO, June 2, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced today that Chief ...

3 months ago - PRNewsWire

Kintara Stock Soars After Site Activation Update On Glioblastoma Trial

Kintara Therapeutics Inc (NASDAQ: KTRA) has announced that the VAL-083 treatment arm in the Global Coalition for Adaptive Research registrational Phase 2/3 trial for glioblastoma multiforme (GBM) has be...

3 months ago - Benzinga

Kintara Therapeutics says VAL-083 treatment arm in the Phase 2/3 clinical trial for glioblastoma multiforme has now b...

Kintara Therapeutics, Inc. (NASDAQ:KTRA) has announced that the VAL-083 treatment arm in the Global Coalition for Adaptive Research (GCAR) registrational Phase 2/3 clinical trial for glioblastoma multif...

3 months ago - Proactive Investors

Kintara Therapeutics, Inc. says VAL-083 treatment arm in the Phase 2/3 clinical trial for glioblastoma multiforme has...

Kintara Therapeutics, Inc. (NASDAQ:KTRA) has announced that the VAL-083 treatment arm in the Global Coalition for Adaptive Research (GCAR) registrational Phase 2/3 clinical trial for glioblastoma multif...

3 months ago - Proactive Investors

Kintara Therapeutics Provides Positive Site Activation Update on GCAR Phase 2/3 Clinical Trial for Glioblastoma

SAN DIEGO, May 26, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies...

3 months ago - PRNewsWire

Kintara Therapeutics draws Buy recommendation from Aegis Capital which maintains a $7 price target

Analysts at Aegis Capital Corp rated Kintara Therapeutics Inc (NASDAQ:KTRA) a 'Buy,' while maintaining a $7 share target price on the company which develops new solid tumor cancer therapies. The San Die...

Other symbols:TGT
4 months ago - Proactive Investors

Kintara Therapeutics ends fiscal 3Q with cash and cash equivalents of about $15.7M

Kintara Therapeutics Inc (NASDAQ:KTRA), which is focused on the development of new solid tumor cancer therapies, said it closed its fiscal third quarter with cash and cash equivalents of about $15.7 mil...

4 months ago - Proactive Investors

Kintara Therapeutics Announces Fiscal Third Quarter 2021 Financial Results and Provides Corporate Update

SAN DIEGO, May 14, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies...

4 months ago - PRNewsWire

Kintara Therapeutics appoints corporate finance veteran Tamara Seymour as its board director

Kintara Therapeutics Inc (NASDAQ:KTRA) has announced the appointment of corporate finance veteran Tamara Seymour to its board of directors. Seymour replaces John Liatos, who will continue in his role as...

4 months ago - Proactive Investors

Kintara Therapeutics Appoints Tamara A. Seymour to Board of Directors

SAN DIEGO, May 4, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,...

4 months ago - PRNewsWire

Kintara Therapeutics says interim Phase 2 study data on VAL-083 shows its potential as game-changing treatment option...

Kintara Therapeutics Inc (NASDAQ:KTRA) has announced interim data from two Phase 2 clinical trials of its lead compound, VAL-083 for glioblastoma multiforme (GBM), which continue to demonstrate its pote...

5 months ago - Proactive Investors

Wall Street starts in the red

10.15am: Proactive North America headlines: Genprex Inc (NASDAQ:GNPX)  presents positive preclinical data for lung cancer drug REQORSA at American Association for Cancer Research meeting Kintara Therape...

Other symbols:ALTGNPX
5 months ago - Proactive Investors

Kintara Presents Updates on Two Phase 2 Clinical Trials at the 2021 American Association for Cancer Research Annual M...

SAN DIEGO, April 12, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company developing novel cancer therapies for patients who are faili...

5 months ago - PRNewsWire

Kintara Taking The Lead In Developing New And Innovative Rare Cancer Therapies

Kintara Therapeutics, Inc. Chief Executive Officer Saiid Zarrabian participated in the Benzinga Biotech Small Cap Conference held March 24-25, 2021.  Kintara Therapeutics, Inc. (NASDAQ: KTRA) a biopharm...

5 months ago - Benzinga